{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.14","upperLimit":"0.34","value":"0.23"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}],"title":"12 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.54","upperLimit":"0.76","value":"0.67"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"1"}]}],"title":"24 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.76","upperLimit":"0.93","value":"0.87"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"1"}]}],"title":"36 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.89","upperLimit":"0.99","value":"0.97"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"1"}]}],"title":"48 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"This is defined as the interval between randomization and date of the first MRI showing at least 35% reduction from baseline in spleen volume. The analysis was performed for participants who achieved a 35% reduction in spleen volume","dispersionType":"95% Confidence Interval","groups":[{"description":"5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule","id":"OG000","title":"Ruxolitinib"},{"description":"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS)","reportingStatus":"POSTED","timeFrame":"Time from randomization and date of the first MRI showing at least 35% reduction from baseline in spleen volume","title":"Time to First at Least 35% Reduction in Spleen Volume From Baseline by Treatment (Primary Analysis)","type":"SECONDARY","unitOfMeasure":"probability of response"}